Showing 8471-8480 of 10141 results for "".
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- Aclaris Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/aclaris-announces-pricing-of-initial-public-offering/2458854/Aclaris Therapeutics, Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares, approved for listing on The NASDAQ Global Select Market, will be traded under the ticker symbol ACRS. All of the common
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142
- Allergan Completes Acquisition of Kybella Maker Kytherahttps://practicaldermatology.com/news/allergan-completes-acquisition-of-kybella-maker-kythera/2458856/Allergan plc has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds Kybella® (deoxych
- DermTube Offers Video Coverage of NewDerm Live Meetinghttps://practicaldermatology.com/news/dermtube-offers-video-coverage-of-newderm-live-meeting/2458865/NewDerm LIVE, a new meeting for dermatologists just starting out in practice—as well as those not so new to practice—has brought a unique meeting format into the dermatology space. The meeting, supported by the publishers of Practical Dermatology® magazine and NewDerm
- Report: Prescription Dermatological Drug Market Exceeds 21 Billion Dollarshttps://practicaldermatology.com/news/report-prescription-dermatological-drug-market-exceeds-21-billion-dollars/2458870/The worldwide market for prescription dermatological drugs exceeded $21 billion last year, according to a report from Kalorama Information. The market research firm said field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options
- Costs, Uncertainty May Cause Consumers to Delay Cosmetic Procedures: ASDShttps://practicaldermatology.com/news/costs-uncertainty-may-cause-consumers-to-delay-cosmetic-procedures-asds/2458886/Cost, fear of suboptimal results, and uncertainty over choosing a provider are the key concerns that may deter prospective patients from receiving cosmetic treatments, new findings from the 2015 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures sh
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- Provectus Receives Patent for Investigational Melanoma Agent PV-10https://practicaldermatology.com/news/provectus-receives-patient-for-investigational-melanoma-agent-pv-10/2458891/Provectus Biopharmaceuticals, Inc. has received a patent from the US Patent and Trademark Office, protecting the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination wit
- Benzac Skin Refining Mask and Benzac Acne Eliminating Cleanser from Galderma Now Available Nationwidehttps://practicaldermatology.com/news/benzac-skin-refining-mask-and-benzac-acne-eliminating-cleanser-from-galderma-now-available-nationwide/2458893/